Identification of a human estrogen receptor α tetrapeptidic fragment with dual antiproliferative and anti-nociceptive action

Area of Science:

• Molecular Pharmacology
• Cancer Biology
• Pain Management

Background:

• The synthetic peptide ERα17p, derived from human estrogen receptor α (ERα), exhibits anti-cancer and anti-nociceptive properties.
• These effects are mediated through interaction with the G protein-coupled estrogen receptor (GPER).
• Structural modeling suggested the N-terminal PLMI motif of ERα17p is crucial for GPER interaction.

Purpose of the Study:

• To investigate the specific role of the PLMI motif in the pharmacological actions of ERα17p.
• To determine the contribution of different peptide regions to GPER-mediated effects.
• To identify potential therapeutic targets for GPER modulation.

Main Methods:

• Peptide synthesis and characterization.
• In vitro assays for antiproliferative and GPER binding.
• In vivo studies for anti-nociceptive and anti-tumor effects.
• Biophysical techniques to assess peptide aggregation.

Main Results:

• The PLMI peptide fragment alone replicates the antiproliferative and anti-nociceptive effects of ERα17p.
• PLMI's activity is dependent on GPER interaction.
• The C-terminal NSLALSLT region of ERα17p is responsible for peptide aggregation.
• PLMI emerges as a key pharmacophore for GPER modulation.

Conclusions:

• The tetrapeptide PLMI is the active component of ERα17p responsible for GPER-mediated antiproliferative and anti-nociceptive effects.
• Targeting GPER with PLMI or its derivatives offers a promising strategy for developing novel therapeutics for breast cancer and pain.
• Modulating GPER is a viable approach for pain control.